NCT03382574 2022-06-14
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Terminated
National Cancer Institute (NCI)
Amgen
University of California, San Francisco
M.D. Anderson Cancer Center
University of Hawaii
Northwestern University